Cardinal Health Q1 FY27: EPS up 27.0%, revenue $67.51B, outlook raised
Cardinal Health opened fiscal 2027 with 5.0% revenue growth to $67.51 billion and raised full-year non-GAAP EPS guidance to $12.80–$13.00. The story is in the profit line, not the top line: non-GAAP operating earnings rose 17.0% while gross margin only reached 3.8%. Read it as a distributor squeezing more out of each dollar of volume, then check the medical segment, where profit fell 28.0%.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS rose 27.0% to $2.38 and non-GAAP rose 28.0% to $3.26, both faster than the 13.0% growth in GAAP operating earnings. The gap came from below the operating line: an effective tax rate of 19.2% versus 24.1% a year ago, plus a lower share count. Non-GAAP operating earnings of $1.00 billion were up 17.0%, and roughly $248 million of charges (including $182 million of amortization and $94 million of acquisition-related compensation) sat outside that figure.
Revenue rose 5.0% to $67.51 billion from $64.01 billion, and virtually all of it came from Pharmaceutical and Specialty Solutions at $62.58 billion, up 6.0%. Global Medical Products and Distribution was flat at $3.19 billion, while Other added $1.76 billion, up 7.0%. This is pass-through volume, not pricing: the segment carrying 92.7% of revenue grew mid-single digits and nothing else moved the needle.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-05
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.